These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36287631)

  • 21. An economic analysis of different treatments for bleeding in patients with acquired haemophilia.
    Kim CH; Simmons SC; Wang D; Najafzadeh P; Azad A; Pham HP
    Vox Sang; 2020 Apr; 115(3):192-199. PubMed ID: 31879973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study.
    Zanon E; Milan M; Gamba G; Ambaglio C; Saggiorato G; Spiezia L; Montani N; Prandoni P
    Thromb Res; 2015 Dec; 136(6):1299-302. PubMed ID: 26505666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab.
    Atsou S; Schellenberg C; Lagrange J; Lacolley P; Lenting PJ; Denis CV; Christophe OD; Regnault V
    J Thromb Haemost; 2024 Jan; 22(1):112-125. PubMed ID: 37776978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
    Young G; Shafer FE; Rojas P; Seremetis S
    Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic Effect of Bypassing Agents and Sequence Identical Analogue of Emicizumab and Fibrin Clot Structure in the In Vitro Model of Hemophilia A.
    Zong Y; Antovic A; Soutari NMH; Antovic J; Pruner I
    TH Open; 2020 Apr; 4(2):e94-e103. PubMed ID: 32704613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor.
    Ogiwara K; Nogami K; Matsumoto T; Shima M
    Int J Hematol; 2014; 99(5):577-87. PubMed ID: 24687919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma.
    Grandoni J; Duretz V; Bonzo D; Evans S; Plantier JL
    Haemophilia; 2021 Mar; 27(2):321-328. PubMed ID: 33550714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
    Holme PA; Brosstad F; Tjønnfjord GE
    Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
    Szmurło D; Deryło Ł; Ryś P; Władysiuk M
    Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.
    Elg M; Carlsson S; Gustafsson D
    Thromb Res; 2001 Feb; 101(3):159-70. PubMed ID: 11228339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.
    Hay JW; Zhou ZY
    Haemophilia; 2011 Sep; 17(5):e969-74. PubMed ID: 21649802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
    Martinowitz U; Livnat T; Zivelin A; Kenet G
    Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Thromb Haemost; 2021 Mar; 121(3):279-286. PubMed ID: 32906155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
    Kizilocak H; Marquez-Casas E; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Sep; 27(5):730-735. PubMed ID: 34115433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activated prothrombin complex concentrate to treat bleeding events in acquired hemophilia A: BAHAS study.
    Mingot-Castellano ME; García-Candel F; Benítez-Hidalgo O; Marco A; Méndez Navarro GA; Pérez-Montes R; García Donas G; Canaro M; Paloma MJ; Asenjo B; Calle-Gordo VM; González NP; Rodríguez González R; Caparrón-Miranda IS; Quintana París L; Herrero S; Nuñez R
    Eur J Haematol; 2022 Dec; 109(6):686-695. PubMed ID: 36029160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emicizumab promotes factor Xa generation on endothelial cells.
    Fager AM; Ellsworth P; Key NS; Monroe DM; Hoffman M
    J Thromb Haemost; 2024 Jun; 22(6):1605-1615. PubMed ID: 38460838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgery in patients with haemophilia and high responding inhibitors: Izmir experience.
    Balkan C; Karapinar D; Aydogdu S; Ozcan C; Ay Y; Akin M; Kavakli K
    Haemophilia; 2010 Nov; 16(6):902-9. PubMed ID: 20518817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.